BIIB — Biogen Inc.
Healthcare · ETF XLV · as of 2026-09-18
Daily · EMA 10 / 20 / 50 · SMA 200 · VolPress: buy/sell split, 20-SMA, white dot = above avg · · E = earnings · RS vs SPY ⓘ · ● RS new high ⓘ
Biogen Inc.
NMS
Healthcare · Drug Manufacturers - General
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar refer...
Price & today
$215.50
ATR(14) 5.63 (2.61%)
| Stock today | -1.62% |
| Sector ETF today | -0.25% |
| Residual (stock-specific) | -1.37% |
Sector correlation
| 20-day correlation with XLV | 0.62 |
| 60-day correlation with XLV | 0.68 |
| Status | normal |
Decoupling fires when 60d corr − 20d corr > 0.20: stock used to track its sector but the relationship has weakened recently.
Technicals
| 10 EMA | $216.75 |
| 20 EMA | $216.11 |
| 50 EMA | $211.66 |
| EMA stack | BULLISH |
| RSI(14) | 50.4 |
| 52-week high distance | +6.47% |
| 52-week low distance | +95.84% |
Signals
| Market F&G | 46.9 |
| Bull% | 12.2% |
| OVTLYR status | SELL (5d) |
| Sector rank | #413 |
| Next earnings | 2026-10-28 (TNS, 39d) |
MarketSmith metrics - our compute
RS Rating
78.3
ADR%
2.4
RMV (tight)
10.0
Ext (ATR>20EMA)
-0.1
Rel Vol
258.0%
U/D 50d
1.16
U/D 25d
1.00
Accum/Dist 25d
2 / 1
EPS YoY
-34.0%
LoD dist
4.0
Off 52w High
4.6%
Above 52w Low
59.2%
1W / 1M
-0.8 / -2.7
Avg $Vol 50d
213.5M
Mkt Cap (B)
31.8
Trend 8/8
YES
Leads Group
YES
Sector XLV
+1.8% 1W
Base len (VCP)
10wk (6/18)
Coil (base shape)
85TVPX
What do these abbreviations mean?
- RS Rating
- - IBD-style relative strength vs SPY (weighted 3/6/9/12-mo). 70+ = leaders pool, 80+ = strong.
- ADR%
- - average daily range over 20 days. 4%+ = the fast movers the playbook prefers (selection order, not a gate).
- RMV (tight)
- - Relative Measured Volatility, 15 bars, scaled 0-100. <15 = tight coiled base (green), <35 moderate, high = loose/expanding - not a base right now.
- Ext (ATR>20EMA)
- - how many ATRs price sits above its 20-EMA. ≤1 = in value (green), >2 = extended/chasing (red) - prefer a pullback.
- Rel Vol
- - latest volume vs the 50-day average. 100% = normal; 140%+ = breakout confirmation.
- U/D 50d / 25d
- - up-day vs down-day volume over the window. 1.1+ = net accumulation (institutions buying); under 0.9 on the 25d = net selling.
- Accum/Dist 25d
- - heavy-volume up days vs heavy-volume down days in the last 25 sessions (close moved 0.2%+ on above-average volume). The institutional-participation footprint; 5+ distribution days = O'Neil caution line.
- LoD dist
- - close distance above the day low in % of ATR (100 = one full ATR off the low). High = strong close.
- Off/Above 52w
- - trend-template legs: within 25% of the 52-week high, at least 25% above the 52-week low.
- Trend 8/8
- - all 8 Minervini Trend Template criteria pass. Discovery floor, NOT an entry signal - entries come from the VCP pivot.
- Base len (VCP)
- - weeks since the VCP base started on the latest scan. 10wk+ bases carry the edge; short stacked bases test below random.
Fundamentals & valuation - reference, not entry inputs
P/E (TTM)
24.5
Fwd P/E
13.4
PEG
-
Price/Book
1.4
Profit margin
13.1%
ROE
7.4%
Debt/Equity
36.5
Rev growth
-7.1%
Analyst target
$207 (-4%)
Analyst rating
BUY
Institutional %
98.2%
Insider %
0.2%
Float %
99.1%
Valuation and analyst figures are Yahoo company stats (weekly refresh, ~3,000 larger names - blanks are honest gaps); logo, employees, website and IPO date are Massive company reference. Momentum/VCP entries do not use valuation - this card is context so you do not have to leave the page.
Company data - context read, not entry inputs
Industry rank
4 / 147
Industry
Drug Manufacturers - General
Float
146.3M
Float turnover 20d
0.6%
Avg $Vol 20d / 50d
176.4M / 213.5M
Days to cover
4.8
Short % float
3.8%
Institutional %
98.2%
Weinstein stage
2
Float, short interest and institutional % come from Yahoo company stats, refreshed weekly for ~3,000 larger names - a blank means Yahoo does not publish the figure for this stock, not that it is zero. Dollar volume and float turnover are computed from our own price bars; industry rank from our rotation data; stage from the weekly chart.
Quarterly EPS - earnings acceleration
A dash in %Chg is deliberate: the year-ago figure was a loss, so a growth % would be meaningless. A dash in Sales means we have no revenue figure for that quarter - read it as a gap in our data, not as zero revenue.
| Quarter | EPS ($) | %Chg YoY | Sales ($M) | %Chg |
|---|---|---|---|---|
| Oct-24 | 4.08 | -6% | 2,465.8 | -3% |
| Feb-25 | 3.44 | +17% | 2,454.7 | +3% |
| May-25 | 3.02 | -18% | 2,431.0 | +6% |
| Jul-25 | 5.47 | +4% | 2,645.5 | +7% |
| Oct-25 | 4.81 | +18% | 2,534.7 | +3% |
| Feb-26 | 1.99 | -42% | 2,279.4 | -7% |
| Apr-26 | 3.57 | +18% | 2,477.8 | +2% |
| Jul-26 | 3.60 | -34% | - | - |
† = SEC carries this same fiscal quarter under a second period-end with a materially different figure (hover for it) - a restatement, merger recast or successor-period split; %Chg is blanked when the two are more than 15% apart. It fires only when the two period-ends DISAGREE, so it is a floor, not a guarantee that the rest of the column shares one basis · ‡ = the revenue concept changed from the previous quarter WITH A FIGURE (hover for both) - a blank row in between is skipped, as the eye does - a step at that row is a change of basis, not necessarily of business · EPS = Yahoo
eps_actual (the figure MarketSmith/Deepvue show) - whether a given quarter is GAAP or excludes a one-off follows the filing, so it can sit either side of another vendor's number; AAPL's Oct-24 row, the Sep-2024 fiscal quarter, is $0.97 here - GAAP, including the EU tax charge - where TradingView's year implies $1.64 · Sales ($M) = SEC EDGAR quarterly revenue (fiscal Q4 derived as FY minus 9-mo) · quarter = report month · %Chg blank = prior-year base under $0.05 (not meaningful).Recent news - our DB (Finnhub + OVTLYR)
- Sep 17 · Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN GlobeNewsWire
- Sep 17 · Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN Yahoo
- Sep 17 · Biogen Announces Publication Of Phase 3 VALIANT Adolescent Subgroup Data In CJASN Demonstrating 75% Proteinuria Reduction For EMPAVELI In Rare Kidney Diseases Benzinga
- Sep 17 · Autoimmune Disease Therapeutics Market Set for Growth Through 2034 as Biologics, Precision Medicine and Pipeline Innovation Reshape the Competitive Landscape GlobeNewswire Inc.
- Sep 17 · Biogen: Growth Is Back, But It Came At A Price SeekingAlpha
- Sep 16 · How AbbVie's Neuroscience Portfolio Has Transformed Over the Years Yahoo
- Sep 16 · Is Biogen Stock Outperforming the S&P 500? Yahoo
- Sep 16 · LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Approved in Japan for the Treatment of Early Alzheimer's Disease GlobeNewsWire